PSMA Theranostics: Current Landscape and Future Outlook
Cancers 2021, 13(16), 4023; https://doi.org/10.3390/cancers13164023, August 10, 2021, by Hanbo [...]
Lu-177-PSMA-617A Added to Standard Therapy
VISION Trail Results Indicate Benefit of 177Lu-PSMA-617A Added to Standard [...]
Theranostic Approach in Breast Cancer
Theranostic Approach in Breast Cancer: A Treasured Tailor for Future [...]
FDA for Lu-177-PSMA-617 for mCRPC treatment
Targeted Oncology, Sarah Karlovitch, June 17, 2021 The FDA has [...]
Global Nuclear Medicine Market 2013-2025
Key slide by MEDraysintell used at the SNMMI virtual meeting [...]
Drugmakers push into radio pharmaceuticals
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 [...]
Asco 2021 justifies Novartis’s radioligand Vision
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves [...]
Theranostics: Reimagining the standard of care
HealthCare Business News magazine, June 2021, Tiffany Olson It may [...]
EANM position paper on the role of radiobiology in nuclear medicine
Aerts, A., Eberlein, U., Holm, S. et al. EANM position [...]
Travel cards could help radiopharma patients avoid delays
April 29, 2020 -- Patients who undergo radiation treatment with lutetium-177 [...]